Arcus Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company whose common stock trades on the New York Stock Exchange under RCUS. Form 8-K reports include quarterly and annual results furnished with pipeline updates, clinical program disclosures, collaboration updates, executive changes and material agreements tied to the company’s financing and development activities.
Arcus filings also cover capital structure and governance matters, including a completed common stock offering, amendments to a loan and security agreement, annual proxy materials, board and executive compensation disclosures, equity incentive matters and stockholder meeting proposals. The filing record reflects risk and operating disclosures connected to drug development, clinical studies, regulatory pathways, collaborations and funding needs.
Arcus Biosciences (RCUS) insider holders filed a notice to sell 50,000 shares of Class A common stock through Goldman Sachs & Co. LLC on the NYSE, with an indicated aggregate market value of $999,500. The filing states that 120,801,086 shares of this class were outstanding at the time referenced, providing context for the planned sale size. The shares were originally acquired from the issuer in private transactions in May 2015. Over the past three months, the same trust has already sold additional Class A shares in several transactions, including 77,167 shares on 10/29/2025 for gross proceeds of $1,617,034.48. The signer represents that they are not aware of undisclosed material adverse information about the company.
Arcus Biosciences (RCUS): Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen filed an amended Schedule 13G reporting beneficial ownership of 4,332,479 Arcus common shares, equal to 4.1% of the class as of September 30, 2025.
The reporting persons have 0 shares with sole voting or dispositive power and 4,332,479 shares with shared voting and shared dispositive power. They certified the holdings were not acquired with the purpose or effect of changing or influencing control.
Arcus Biosciences (RCUS) reported an insider transaction by its Chief Operating Officer. On 11/07/2025, the officer exercised 50,291 stock options at $1.2276 per share and sold 50,291 common shares at a $18.9709 weighted average price under a Rule 10b5-1 trading plan. After these trades, the officer directly held 214,232 common shares. The filing notes the sales occurred across multiple trades between $18.59 and $19.42. Remaining derivative holdings include 80,583 stock options with an expiration date of 03/14/2027.
Gilead Sciences filed Amendment No. 6 to its Schedule 13D on Arcus Biosciences, updating its beneficial ownership and voting power disclosures. Gilead reports beneficial ownership of 31,424,760 shares of Arcus common stock, representing 25.6% of the class. Gilead has sole voting and dispositive power over the same 31,424,760 shares and no shared power.
The percentage is based on 122,856,086 shares outstanding as reported in a prospectus supplement dated October 31, 2025. The filing details prior purchases under multiple purchase agreements and offerings. It also notes that Jeffrey A. Bluestone holds options exercisable within 60 days for 10,750 shares, equating to 0.01% on an as‑converted basis.
Arcus Biosciences (RCUS): The company’s President reported an open‑market sale of 4,314 shares of common stock on 10/30/2025 at a weighted average price of $20.3175, executed under a Rule 10b5‑1 trading plan adopted on August 12, 2024.
Following the transaction, the reporting person beneficially owned 1,087,060 shares indirectly (by trust) and 367,220 shares directly. The price reflected multiple trades between $20.12 and $20.63.
Arcus Biosciences (RCUS) completed an underwritten public offering of common stock. The company sold 15,755,000 shares, including the full exercise of the underwriters’ 2,055,000-share option, and received net proceeds of approximately $269.7 million after discounts and expenses.
The shares were offered at a public price of $18.25 per share, with underwriters purchasing at $17.155 per share. The transaction was conducted under an effective Form S-3 registration, with Leerink Partners LLC and Goldman Sachs & Co. LLC acting as representatives of the underwriters. The offering closed on November 3, 2025.
Arcus Biosciences (RCUS) launched a primary offering of 13,700,000 shares of common stock at $18.25 per share. The transaction is expected to generate gross proceeds of $250,025,000, less underwriting discounts of $15,001,500, for proceeds to the company before expenses of $235,023,500. Arcus also granted the underwriters a 30‑day option to purchase up to 2,055,000 additional shares.
Arcus estimates net proceeds of approximately $234.5 million (or approximately $269.7 million if the option is exercised in full). The company plans to use the funds to advance R&D, including expansion of the casdatifan program and development of immunology and inflammation candidates, and for general corporate purposes. Based on 107,101,086 shares outstanding as of September 30, 2025, new investors would face an immediate dilution of $12.70 per share at the offering price. A 60‑day lock‑up applies to the company and insiders, subject to customary exceptions. The shares are expected to be delivered on or about November 3, 2025.
Arcus Biosciences (RCUS) holder filed a Form 144 to sell 1,173 shares of Class A Common Stock with an aggregate market value of $23,682.87, approximately on October 30, 2025, through Goldman Sachs & Co. LLC on the NYSE.
The notice also lists recent sales by the same account: 19,019 shares for $383,944.16 on October 28, 2025; 76,667 shares for $1,600,791.63 on October 29, 2025; 1,173 shares for $25,844.94 on October 29, 2025; and 3,141 shares for $63,817.27 on October 30, 2025. Shares outstanding were 107,973,536; this is a baseline figure, not the amount being sold.
Arcus Biosciences (RCUS) holder filed a Form 144 to sell 1,173 shares of Class A Common Stock with an aggregate market value of $23,682.87, approximately on October 30, 2025, through Goldman Sachs & Co. LLC on the NYSE.
The notice also lists recent sales by the same account: 19,019 shares for $383,944.16 on October 28, 2025; 76,667 shares for $1,600,791.63 on October 29, 2025; 1,173 shares for $25,844.94 on October 29, 2025; and 3,141 shares for $63,817.27 on October 30, 2025. Shares outstanding were 107,973,536; this is a baseline figure, not the amount being sold.
Arcus Biosciences plans a primary offering of common stock under its effective shelf registration. Leerink Partners and Goldman Sachs are joint bookrunners, and the company expects to grant a 30‑day option to the underwriters to purchase additional shares. Arcus’s common stock trades on the NYSE under “RCUS”; the last reported sale price was $20.29 on October 29, 2025.
The company states that net proceeds will fund ongoing research and development, including expansion of the casdatifan (HIF‑2α) clinical program, discovery and development in its immunology and inflammation portfolio, and for general corporate purposes such as working capital and operating expenses. A 60‑day lock‑up applies to the company and certain insiders, subject to customary exceptions.
Shares outstanding were 107,101,086 as of September 30, 2025; this is a baseline figure, not the amount being offered.
Arcus Biosciences plans a primary offering of common stock under its effective shelf registration. Leerink Partners and Goldman Sachs are joint bookrunners, and the company expects to grant a 30‑day option to the underwriters to purchase additional shares. Arcus’s common stock trades on the NYSE under “RCUS”; the last reported sale price was $20.29 on October 29, 2025.
The company states that net proceeds will fund ongoing research and development, including expansion of the casdatifan (HIF‑2α) clinical program, discovery and development in its immunology and inflammation portfolio, and for general corporate purposes such as working capital and operating expenses. A 60‑day lock‑up applies to the company and certain insiders, subject to customary exceptions.
Shares outstanding were 107,101,086 as of September 30, 2025; this is a baseline figure, not the amount being offered.
Arcus Biosciences (RCUS) reported insider transactions by its President. On 10/28/2025, an indirect trust sold 19,019 shares at a weighted average price of $20.1874 (range $20.00–$20.36). On 10/29/2025, the trust sold 47,675 shares at $20.4894 (range $20.00–$20.99), 29,365 shares at $21.5279 (range $21.02–$22.01), and 800 shares at $22.0441 (range $22.035–$22.055), all pursuant to a Rule 10b5-1 plan adopted on August 12, 2024. Following the reported transactions, beneficial holdings were 1,091,374 shares indirect (by trust) and 367,220 shares direct.
Arcus Biosciences (RCUS) reported insider transactions by its President. On 10/28/2025, an indirect trust sold 19,019 shares at a weighted average price of $20.1874 (range $20.00–$20.36). On 10/29/2025, the trust sold 47,675 shares at $20.4894 (range $20.00–$20.99), 29,365 shares at $21.5279 (range $21.02–$22.01), and 800 shares at $22.0441 (range $22.035–$22.055), all pursuant to a Rule 10b5-1 plan adopted on August 12, 2024. Following the reported transactions, beneficial holdings were 1,091,374 shares indirect (by trust) and 367,220 shares direct.